May 22, 2019 | METH in the news
…about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
May 20, 2019 | General News
Little Rock, AR (20 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced that its Board of Managers has appointed Keith W. Ward, Ph.D., to serve as...
May 13, 2019 | General News
Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team...
Recent Comments